Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele.

Autoimmune lymphoproliferative syndrome type Ia (ALPS Ia) is caused by mutations in the CD95/APO1/FAS (TN-FRSF6) gene, which lead to a defective CD95 ligand (CD95L)-induced apoptosis. Soluble CD95 (sCD95) has been suggested to play an important role in the pathogenesis of diverse autoimmune and malignant diseases by antagonizing CD95L. Here we evaluate a family with 4 of its 5 members harboring an ex-6-3C-->G mutation that affects the splice cis regulatory region (cctacag/ex-6-->cctagag/ex-6) of the CD95 gene. The mutation causes skipping of exon-6, which encodes the transmembrane region of CD95, and thereby leads to an excessive production of sCD95 in all 4 affected individuals. The mutation is associated with a low penetrance of disease phenotype and caused mild and transient ALPS in one male patient whereas all other family members are completely healthy. In all family members with the mutation we found that the cell surface expression of CD95 was low and the activated T cells were resistant to CD95-induced apoptosis. Unexpectedly, excessive production or addition of sCD95 had no effect on the CD95-induced apoptosis in diverse cells. In contrast, increasing the surface expression of CD95 was able to correct the defect in apoptosis. Thus we conclude that the ALPS in the one male patient was caused by haploinsufficiency of membrane CD95 expression. Our data challenge the hypothesis that sCD95 causes autoimmunity.

[1]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.

[2]  F. Uckun,et al.  CD95 (APO‐1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants , 2003, European journal of haematology.

[3]  T. Dull,et al.  Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. , 2002, Blood.

[4]  Thierry Lamy,et al.  Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. , 2002, Blood.

[5]  P. Huie,et al.  Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. , 2002, Blood.

[6]  J. Puck,et al.  Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. , 2001, Blood.

[7]  A. Marx,et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.

[8]  J. Valcárcel,et al.  The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. , 2000, Molecular cell.

[9]  J K Frederiksen,et al.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.

[10]  U. Dianzani,et al.  Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. , 2000, Blood.

[11]  M. Tomonaga,et al.  Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO‐1) in adult T‐cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis , 1999, British journal of haematology.

[12]  Shigeki Tanaka,et al.  mRNA expression of variant fas molecules in acute leukemia cells , 1999, American journal of hematology.

[13]  J. Puck,et al.  Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.

[14]  S. Baekkeskov,et al.  A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. , 1999, Transplantation.

[15]  M. Gahr,et al.  Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. , 1999, Experimental hematology.

[16]  M. Peter,et al.  Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Puck,et al.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. , 1999, American journal of human genetics.

[18]  P. Krammer,et al.  The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. , 1999, The Journal of clinical investigation.

[19]  Jane Y. Wu,et al.  Alternative splicing and programmed cell death. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[20]  J. Puck,et al.  The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. , 1998, The Journal of pediatrics.

[21]  Y. Rao,et al.  Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Jaffe,et al.  Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. , 1997, Blood.

[24]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[25]  L. Notarangelo,et al.  Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. , 1997, Blood.

[26]  K. Sullivan,et al.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.

[27]  F. Rieux-Laucat,et al.  Clinical, immunological, and pathological consequences of Fas-deficient conditions , 1996, The Lancet.

[28]  P. Schur,et al.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.

[29]  H. Horvitz,et al.  An Alternatively Spliced C. elegans ced-4 RNA Encodes a Novel Cell Death Inhibitor , 1996, Cell.

[30]  G. Starace,et al.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. , 1996, Journal of immunology.

[31]  J. Mountz,et al.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.

[32]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[33]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[34]  A. Strasser,et al.  Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. , 1995, Current opinion in immunology.

[35]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[36]  E. Alnemri,et al.  Cloning and Expression of Four Novel Isoforms of Human Interleukin-1β Converting Enzyme with Different Apoptotic Activities (*) , 1995, The Journal of Biological Chemistry.

[37]  L. Wang,et al.  Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death , 1994, Cell.

[38]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[39]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[40]  E. Jaffe,et al.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. , 1992, The Journal of clinical investigation.

[41]  Virginia C. Canale,et al.  Chronic lymphadenopathy simulating malignant lymphoma. , 1966, The Journal of pediatrics.

[42]  J. Mountz,et al.  Regulation of apoptosis in immune cells , 2005, Journal of Clinical Immunology.

[43]  G Ruberti,et al.  Soluble Fas/Apo-1 splicing variants and apoptosis. , 1996, Frontiers in bioscience : a journal and virtual library.

[44]  J. Russell,et al.  Activation-induced death of mature T cells in the regulation of immune responses. , 1995, Current opinion in immunology.